Stock Scorecard
Stock Summary for Alnylam Pharmaceuticals Inc (ALNY) - $331.91 as of 7/4/2025 12:30:45 AM EST
Total Score
6 out of 30
Safety Score
46 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for ALNY
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for ALNY
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for ALNY
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for ALNY
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for ALNY (46 out of 100)
| Stock Price Rating (Max of 10) | 10 |
| Historical Stock Price Rating (Max of 10) | 10 |
| Stock Price Trend (Max of 10) | 9 |
| Book Value (Max of 10) | 1 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 5 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 1 |
| Trading Volume (Max of 10) | 5 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for ALNY
Financial Details for ALNY
Company Overview |
|
|---|---|
| Ticker | ALNY |
| Company Name | Alnylam Pharmaceuticals Inc |
| Country | USA |
| Description | Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts. |
| Sector Name | LIFE SCIENCES |
| Industry Name | PHARMACEUTICAL PREPARATIONS |
| Most Recent Quarter | 3/31/2025 |
| Next Earnings Date | 7/30/2025 |
Stock Price History |
|
| Last Day Price | 331.91 |
| Price 4 Years Ago | 169.58 |
| Last Day Price Updated | 7/4/2025 12:30:45 AM EST |
| Last Day Volume | 431,157 |
| Average Daily Volume | 909,195 |
| 52-Week High | 330.00 |
| 52-Week Low | 205.87 |
| Last Price to 52 Week Low | 61.22% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 21.93 |
| Sector PE | 40.90 |
| 5-Year Average PE | -6,575.04 |
| Free Cash Flow Ratio | 42.44 |
| Industry Free Cash Flow Ratio | 17.71 |
| Sector Free Cash Flow Ratio | 32.91 |
| Current Ratio Most Recent Quarter | 3.04 |
| Total Cash Per Share | 7.82 |
| Book Value Per Share Most Recent Quarter | 0.89 |
| Price to Book Ratio | 372.49 |
| Industry Price to Book Ratio | 34.53 |
| Sector Price to Book Ratio | 30.76 |
| Price to Sales Ratio Twelve Trailing Months | 18.31 |
| Industry Price to Sales Ratio Twelve Trailing Months | 121.97 |
| Sector Price to Sales Ratio Twelve Trailing Months | 35.60 |
| Analyst Buy Ratings | 12 |
| Analyst Strong Buy Ratings | 11 |
Share Statistics |
|
| Total Shares Outstanding | 130,388,000 |
| Market Capitalization | 43,277,081,080 |
| Institutional Ownership | 97.50% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 2.52% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | 36.82% |
| Reported EPS 12 Trailing Months | -2.11 |
| Reported EPS Past Year | -0.01 |
| Reported EPS Prior Year | -1.46 |
| Net Income Twelve Trailing Months | -269,701,000 |
| Net Income Past Year | -278,157,000 |
| Net Income Prior Year | -440,242,000 |
| Quarterly Revenue Growth YOY | 20.20% |
| 5-Year Revenue Growth | 59.21% |
| Operating Margin Twelve Trailing Months | 3.04% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 1,019,654,000 |
| Total Cash Past Year | 966,428,000 |
| Total Cash Prior Year | 812,688,000 |
| Net Cash Position Most Recent Quarter | -5,912,000 |
| Net Cash Position Past Year | -58,193,000 |
| Long Term Debt Past Year | 1,024,621,000 |
| Long Term Debt Prior Year | 1,020,776,000 |
| Total Debt Most Recent Quarter | 1,025,566,000 |
| Equity to Debt Ratio Past Year | 0.06 |
| Equity to Debt Ratio Most Recent Quarter | 0.10 |
| Total Stockholder Equity Past Year | 67,088,000 |
| Total Stockholder Equity Prior Year | -220,644,000 |
| Total Stockholder Equity Most Recent Quarter | 115,435,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -75,385,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -0.58 |
| Free Cash Flow Past Year | -42,589,000 |
| Free Cash Flow Prior Year | 41,945,000 |
Options |
|
| Put/Call Ratio | 1.35 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 10.18 |
| MACD Signal | 10.02 |
| 20-Day Bollinger Lower Band | 211.18 |
| 20-Day Bollinger Middle Band | 272.93 |
| 20-Day Bollinger Upper Band | 334.69 |
| Beta | 0.21 |
| RSI | 68.43 |
| 50-Day SMA | 264.07 |
| 150-Day SMA | 215.06 |
| 200-Day SMA | 202.26 |
System |
|
| Modified | 7/3/2025 6:03:58 PM EST |